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COVID-19 reinfections 




confirmed events in 
west Africa
At the beginning of the COVID-19 
pandemic, in early 2020, the scientific 
community hypothesised that SARS-
CoV-2 transmission would eventually 
be hindered by herd immunity, 
conferred by natural infection, 
vaccination, or both.1 However, 
essential questions about whether 
infection with SARS-CoV-2 confers 
protection against reinfection and 
the length of time the protection lasts 
after either infection or vaccination 
remain open. These answers are crucial 
for the development of appropriate 
health control measures worldwide 
and become more important as new 
viral variants spread.
By March 15, 2021, fewer than 
100 reinfections had been reported 
worldwide, mainly in countries 
with a high mortality burden. In 
most cases, reinfections were less 
severe than the initial infection.2,3 
However, recent reports from Brazil, 
a country that in parts surpassed the 
threshold of herd immunity after the 
first wave but had a similarly strong 
second wave,4 are worrisome. Such 
resurgence of COVID-19 cases in the 
second wave can be explained by rapid 
waning immunity, the expansion of 
the new SARS-Co-V-2 variants that 
might evade immunity generated 
in response to previous infections 
(ie, B.1.1.7, B.1.351, and P.1), higher 
transmissibility of new lineages that 
require a larger herd immunity, or a 
combination of all these factors.4
Reinfections in west Africa, a region 
with a lower toll of infections and 
deaths5 than Europe, North America, 
or South America, are yet to be 
described. We aimed to ascertain 
whether any reinfections had occurred 
in The Gambia. 
The Gambia is the smallest country 
in west Africa, with 4712 cases and 
150 deaths reported by March 1, 2021, 
although the number of cases is 
probably underestimated.5 At that 
time, 460 SARS-CoV-2 genomes from 
confirmed cases had been sequenced 
in the country, with 430 (93·5%) 
genomes already submitted on the 
GISAID database.6 Among these 
samples, only two main lineages of 
the virus, lineages A and B, have been 
detected. Lineage B constitutes almost 
98% of the total genomes sequenced, 
with the sub-lineage B.1 being the 
most prevalent, found in 20% of 
the sequences. Naso-oropharyngeal 
samples are collected as part of the 
national surveillance and by the 
Medical Research Council Unit The 
Gambia (MRCG) at the London School 
of Hygiene and Tropical Medicine 
through clinical, occupational health, 
and research activities, including 
the PaTS trial (NCT04703608), 
from symptomatic individuals or 
contacts of known COVID-19 cases. 
Screening of asymptomatic health-
care workers and those proposing to 
travel across international borders 
also takes place. The standard test for 
COVID-19 diagnosis in The Gambia, 
as of March 15, 2021, is real-time 
PCR of SARS-CoV-2 specific viral gene 
sequences.
Confirmation of reinfections were 
done by genomic analysis. Library 
preparation and sequencing were 
done using the ARTIC (version 3) 
protocol for SARS-CoV-2 that targeted 
whole genome sequencing.7 Libraries 
were pooled in multiplexes of 
24 per flow cell and sequenced on a 
GridION platform (Oxford Nanopore 
Technologies, UK). Bioinformatics 
analysis was done using the ARTIC 
Patient A Patient B
Sex Female Female
Age, years 31 36 
Comorbidities None None
First infection
Date of infection Aug 30, 2020 July 31, 2020
Clinical presentation WHO criteria for mild infection* Asymptomatic
Ct value ORF-1/ 
N gene
36·7/34·1 Negative/38·0
Lineage B.1 (discovered in March, 2020, in the UK, Mexico, and USA) B.1.235 (discovered January, 2020, in the UK, USA, and Spain)
Second infection
Date of infection Jan 21, 2021 Feb 1, 2021
Clinical presentation WHO criteria for mild infection* WHO criteria for mild infection*
Ct value E gene/ 
N gene
34·0/33·1 20·9/19·1
Lineage B.1.1.74 (discovered in March, 2020, in the UK, Ireland, and Belgium) B.1 (discovered in March, 2020, in the UK, Mexico, and USA)
Ct=cycle threshold. ORF-1=open reading frame 1. *Symptomatic patient meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia. 
Table: Clinical, epidemiological, and molecular characteristics of the two individuals with SARS-CoV-2 reinfections
Lancet Glob Health 2021
Published Online 




2 www.thelancet.com/lancetgh   Published online June 3, 2021   https://doi.org/10.1016/S2214-109X(21)00213-8
Bakary Sanyang, Abdoulie Kanteh, 
Effua Usuf, Behzad Nadjm, 
Sheikh Jarju, Alasana Bah, 
Abdoulie Bojang, Mary Grey-Johnson, 
Joquina Chiquita Jones, Abdou Gai, 
Catherine Sarr, Fatoumata Sillah, 
Oghenebrume Wariri, Francis Oko, 
Carla Cerami, Karen Forrest, 
Alhagie Papa Sey, Haruna Jallow, 
Davis Nwakanma, Abdul Karim Sesay, 
Umberto D’Alessandro, *Anna Roca
aroca@mrc.gm
Medical Research Council Unit The Gambia at the 
London School of Hygiene and Tropical Medicine, 
Fajara 273, The Gambia (BS, AK, EU, BN, SJ, Aba, 
Abo, MG-J, JCJ, AG, CS, FS, OW, FO, CC, KF, DN, AKS, 
UD, AR); National Public Health Laboratories, Kotu, 
The Gambia (APS, HJ)
1 Fontanet A, Cauchemez S. 1Fontanet A, 
Cauchemez S. COVID-19 herd immunity: 
where are we? Nat Rev Immunol 2020; 
20: 583–84.
2 Lee JS, Kim SY, Kim TS, et al. Evidence of severe 
acute respiratory syndrome coronavirus 2 
reinfection after recovery from mild 
coronavirus disease 2019. Clin Infect Dis 2020; 
published online Nov 21. https://doi.
org/10.1093/cid/ciaa1421.
3 Hansen CH, Michlmayr D, Gubbels SM, 
Mølbak K, Ethelberg S. Assessment of protection 
against reinfection with SARS-CoV-2 among 
4 million PCR-tested individuals in Denmark in 
2020: a population-level observational study. 
Lancet 2021; 397: 1204–12.
4 Sabino EC, Buss LF, Carvalho MPS, et al. 
Resurgence of COVID-19 in Manaus, Brazil, 
despite high seroprevalence. Lancet 2021; 
397: 452–55.
5 Worldometer. COVID-19 coronavirus 
pandemic. https://www.worldometers.info/
coronavirus/ (accessed April 5, 2021).
6 GISAID. Phylodynamics of pandemic 
coronavirus in west Africa. 2021. https://www.
gisaid.org/phylodynamics/west-africa/ 
(accessed April 5, 2021).
7 Quick J. nCoV-2019 sequencing protocol v3 
(LoCost) V.3. 2020. https://www.protocols.io/
view/ncov-2019-sequencing-protocol-v3-
locost-bh42j8ye (accessed March 1, 2021).
8 Loman N, Rowe W, Rambaut A. nCoV-2019 




9 Thorvaldsdóttir H, Robinson JT, Mesirov JP. 
Integrative Genomics Viewer (IGV): high-
performance genomics data visualization and 
exploration. Brief Bioinform 2013; 14: 178–92.
10 GISAID. CoVsurver: mutation analysis of 
hCoV-19. https://www.gisaid.org/epiflu-
applications/covsurver-mutations-app/ 
(accessed Feb 17, 2021). 
11 GitHub. Pangolin. 2020. https://github.com/
cov-lineages/pangolin (accessed March 1, 2021).
12 Huang Y, Yang C, Xu XF, Xu W, Liu SW. 
Structural and functional properties of SARS-
CoV-2 spike protein: potential antivirus drug 
development for COVID-19. Acta Pharmacol Sin 
2020; 41: 1141–49.
during SARS-CoV-2 infection in 
vitro.15 One such mutation is N440K, 
detected in patient A’s reinfection. 
Other mutations identified include 
A1020S, which is involved in 
viral oligomerisation interfaces; 
and G946V, detected in the last 
quarter of 2020 among different 
variants, including B.1.1.7. Overall, 
these reinfections are potentially a 
consequence of divergent mutations 
enhancing transmission of the virus, 
but this will need to be assessed in a 
larger pool of reinfected individuals. 
Two (B.1·235 and B.1.1.74) of the 
three lineages involved in these 
two reinfections are uncommon in 
the country, representing 3% and 
less than 1% of the Gambian isolates, 
respectively.6
In summary, our data conclude that 
at least two reinfections have occurred 
in The Gambia. These events have 
occurred in healthy young individuals 
infected with similar viral variants in the 
first and second episode. If reinfections 
with similar strains are possible, 
herd immunity in west Africa could 
take longer than expected as a large 
majority of cases are asymptomatic or 
with mild disease and these probably 
develop weaker immune responses.16 In 
the absence of widespread vaccination, 
reinfections could become more 
common when the new variants 
become predominant in the region. 
Community-based immunological 
studies are urgently needed.
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(version 3) bioinformatics pipeline 
for SARS-CoV-2 genome analysis.8 
Genome alignments against the 
reference were visualised on the 
Interactive Genomics Viewer.9 
Mutations were confirmed using 
the GISAID CoVsurver.10 Lineage 
assignment was done using Pangolin 
(version 2.3.0).11 The Gambian 
Government and MRCG joint ethics 
committee approved the study 
presented here (Ref L2021.E04).
We have phylogenetically confirmed 
two reinfections among healthy 
Gambian individuals aged 31 years and 
36 years, with a time lag of 5 months 
and 6 months, respectively. Both 
individuals had mild symptoms during 
the second infection that lasted less 
than 1 week. For the initial infection, 
one individual had mild symptoms, 
whereas the other was asymptomatic 
(tested as a contact of a positive 
case). Epidemiological, clinical, and 
molecular details of both infections are 
shown in the table.
G e n o m e - w i d e  s e q u e n c e 
comparisons for the two viruses of 
each patient to the reference shows 
mutations on the S gene, which 
encodes for the virus spike protein 
(appendix p 3). The spike protein 
mediates receptor recognition and 
binding during infection, playing an 
important part in viral transmission.12 
Although it is still unclear as to what 
extent immune responses against a 
previous variant will protect against 
reinfection by a different variant, 
mutations of the viral spike protein 
are predicted to enhance infectivity.13 
In both patients, we have seen more 
mutations in the S gene in the variants 
from the second infection episodes 
than in those from the first episode 
(two amino-acid changing mutations 
in the first infection and four in 
the second infection). One of these 
mutations associated with enhanced 
infectivity (D614G)14 was present in 
all four infections. Certain mutations 
on the receptor-binding domain of 
the spike protein confer resistance 
to commonly elicited antibodies 
See Online for appendix
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